Introduction
The eradication of Helicobacter pylori by the administration of oral antimicrobial agents results in resolution of H. pylori-associated gastroduodenal disease. However, such treatment is not always successful in eradicating the bacterium and may be associated with adverse effects. 1 In a previous study using a gnotobiotic murine model, 2 we found that orally adminstered lactobacilli can efficiently eradicate H. pylori. Based on that study, we screened 203 strains of lactobacilli to select strains that exhibited high levels of binding to gastric epithelium and resistance to gastric acidity, and selected strain Lactobacillus gasseri OLL2716 (LG21) as the most suitable for trials in humans (unpublished data). In the present study, we examined the efficacy of this lactobacillus strain as a probiotic against H. pylori in infected individuals.
Materials and methods
The subjects consisted of 29 males and two females aged 50.1 Ϯ 7.4 (mean Ϯ S.D.) years without any evidence of other gastroduodenal disease. Infection with H. pylori was diagnosed on the basis of both positive serology and a [ 13 C]urea breath test (UBT).
The exclusion criteria included antecedent therapy with antibiotics in the previous month, prior treatment with acid-suppressive anti-inflammatory drugs or a history of gastric surgery. Informed consent was obtained and the study was approved by the ethics committee of our university.
The study was conducted in two parts. In the first part, 90 g of yogurt was consumed by the subjects twice daily for 8 weeks. In the second phase, which commenced 1 week following the completion of the first part, subjects received 90 g of yogurt containing LG21 twice daily for a further 8 weeks. The numbers of LG21 in this product were within the range 1-1.4 ϫ 10 7 cfu/g immediately after preparation. LG21-containing yogurt was consumed within 1 week of preparation. Numbers of LG21 in yogurt decreased by approximately 50% following 1 week of storage.
Serum pepsinogen (PG) I and II determination was performed, using a radioimmunoassay, on three occasionsbefore the start of the study (week 0), 1 week after finishing the first part of the study (week 9) and 1 week after finishing the second part of the study (week 18). Levels of PGI and PGII are significantly higher in individuals with gastric mucosal inflammation, with the rise in PGII greater than that of PGI. 3 UBTs were also performed on overnightfasted subjects at these times. A baseline sample of expiratory air was obtained just before the ingestion of 100 mg of [ 13 C]urea diluted in 20 mL water and another sample obtained 10 min later. Excess 13 CO 2 was measured by isotope mass spectrometry. Values Ͼ5 were considered as a positive result. 4 In addition, specimens of gastric antrum were obtained at endoscopy during weeks 9 and 18 from six randomly selected subjects. The paired Wilcoxon signed rank test was used for statistical analysis and P Ͻ 0.05 was considered statistically significant. 
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The treatment regimen was well tolerated and subjects did not complain of any gastrointestinal symptoms whilst receiving LG21-containing yogurt.
The density of H. pylori colonization in the stomach is of importance in the pathogenesis of infection associated with this bacterium. Khulusi et al. 5 reported that no duodenal ulceration was present in subjects with antral H. pylori densities of Ͻ10 5 cfu/mg tissue protein and that there was a correlation between bacterial viable counts and the severity and activity of H. pylori-associated gastritis. PGI/II ratios and UBT, as used in the present study, also provide semi-quantitative assessments of the density of H. pylori colonization of gastric mucosa. 3, 6 Serial UBTs were performed on 29 subjects (Figure 1) . Whilst there was no significant difference in the results obtained at weeks 0 and 9, the results obtained at week 18 were significantly lower than those for the earlier weeks. However, three subjects whose excess 13 CO 2 levels were Ͻ5 at week 18, had levels Ͼ5 3 months later, suggesting that H. pylori had not been eradicated completely (or that reinfection had occurred). PGI/II ratios were determined in 30 subjects. There was a significant change in PGI/II ratio following LG21 treatment, which was not observed following consumption of non-LG21-supplemented yogurt (Figure 2) . Examination of antral biopsies showed two-to 100-fold decreases in the numbers of H. pylori, but in no case were bacteria eliminated completely.
Recently, Michetti et al. 4 reported that a whey-based culture supernatant of Lactobacillus acidophilus La1 has a partial, acid-independent, long-term suppressive effect on H. pylori in humans. In the present study, suppression of H. pylori as determined by UBT and antral biopsy was similarly incomplete. Nevertheless, significant improvements in the degree of gastric inflammation as demonstrated by PGI/II levels were observed and further investigations into the role of probiotics in the therapy of H. pylori-associated gastroduodenal infection are indicated. 
